SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.68-2.4%Dec 12 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: schzammm who wrote (6119)4/10/2002 10:02:42 AM
From: Biomaven  Read Replies (1) of 52153
 
<Isotechnika>

I looked again at the Isotechnika drug, which is a cyclosporine analog that looks to have a clearly better therapeutic window. Cyclosporine is a better than $1 billion drug despite its known toxicity, and if this new candidate's results hold up in the clinic it will completely replace cyclosporine.

There is a detailed presentation describing the pre-clinical and some clinical results at:

newswire.ca

With some Roche muscle behind them the trials should proceed much more quickly.

Note also that this drug is a sleeper psoriasis candidate as well - cyclosporine works very well in psoriasis but the tox concerns prevent its widespread use.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News